BOD Australia Ltd - First medicinal cannabis prescriptions received in the UK
BOD Australia Ltd (ASX:BDA)

First medicinal cannabis prescriptions received in the UK


What's happened?

Bod Australia Ltd (ASX: BDA, “Bod”) has received its first prescriptions for MediCabilis™ from patients in the United Kingdom.

What are the key highlights?

  1. The prescriptions were received from a leading medicinal cannabis organisation, which has a number of clinics in London and the UK more broadly.
  2. The United Kingdom is a major market opportunity for Bod with approximately 7.3m consumers using CBD annually. It is expected to grow in value to US$3Bn per annum by 2024 and to €8.8Bn by 2028. This would represent a market four times larger than Australia in 2028.
  3. With a presence in Australia and now the United Kingdom, Bod expects prescription volumes to increase materially in the coming months, particularly as brand awareness for MediCabilis™ grows amongst physicians and patients in the UK.

What does this announcement mean?

SmallCapInsider from Mawson Graham provides perspective on this recent announcement.
Written by SmallCapInsider
Published May 04, 2020

Bod Australia ("Bod") continues to execute by building on its channels to market both domestically and internationally. Bod also continues to state that prescription growth will increase substantially in the near term. This is following up from already strong previous historical quarter-on-quarter growth from Q2 to Q3 of FY2020 of 135% (from A$0.536m to $1.257m).

The information within this section has been provided by Mawson Graham Pty Ltd and is for general information purposes only and is not intended to reflect any recommendations or financial advice. The information in this section has been prepared without taking into account your objectives, financial situation or needs. For this reason, you should consider the appropriateness of the advice or recommendation in light of your own personal circumstances, relevant risk factors, the nature and extent of your risk of loss, as well as the legal and accounting consequences before acting making an investment or trading decision regarding any Financial Product mentioned herein. While it is believed that all information sourced and contained within this section to be accurate at the time of publication, liability for any errors, omissions, accuracy or completeness of the information (except any statutory liability which cannot be excluded) is specifically excluded by Mawson Graham Pty Ltd, its associates, officers, directors, employees and agents. Past performance is not a reliable indicator of future performance. Important Disclosure: Mawson Graham Pty Ltd, its directors, associates and employees advise that they may hold securities, may have an interest in and/or earn brokerage, investor relations fees, corporate fees, and other benefits or advantages, either directly or indirectly from client transactions arising from any information mentioned within this section and in documents published within this section.
Mawson Graham
Mawson Graham

CEO's Summary

Jo Patterson

"Securing the first international prescriptions for MediCabilis™ has been months in the making and it is the critical catalyst for a rapid increase in prescription volumes in the United Kingdom. Our UK market entry has included rigorous patient and physician education initiatives, as well as collaborative work with our distribution partners to ensure we have the necessary infrastructure in place to scale operations rapidly. This is not quickly or easily replicated, so we have an immediate market advantage here. Bod is now actively engaging with physicians and medical organisations across the UK in a bid to further educate them about the MediCabilis™ range. We are encouraged by the response we are receiving and growing patient demand underpins our confidence that this will be a major growth market for MediCabilis™. The UK is spearheading Bod’s international expansion efforts and will act as the springboard into Europe. We have a large number of growth initiatives underway, including new market entries and product introductions. We look forward to communicating our successes.”

Jo Patterson
CEO, BOD Australia Ltd

Download Announcement

View this announcement as well as our full profile on the company.

How do I invest?

Considering investing in BOD Australia Ltd?
Here's how to get started.
Low Cost Brokerage ASX Cheapest ASX Trading Platform
  1. 1

    Create account

    Open an account with an online broker of your choice. If you do not have an existing broker, consider Mawson Graham's A$9.50 flat fee platform.

    Sign up now »
  2. 2

    Search for ASX:BDA

    On your online investment platform search for the stock ticker code ASX:BDA to bring up the company's shares.

  3. 3

    Buy shares

    Place your order however you wish. If you need advice on buying or selling, you should seek the assistance of a full service financial adviser experienced in small cap equities.